

DAFTAR PUSTAKA

1. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014;27:911-39.
2. Kadowaki H, Akazawa H, Ishida J, et al. Cancer Therapeutics-Related Cardiac Dysfunction — Insights from Bench and Bedside of Onco-Cardiology —. *Circ J*. 2020;84(9):1446–53.
3. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Eur Heart J*. 2016;37(36):2768–801.
4. Bloom MW, Hamo CE, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. *Circ Hear Fail*. 2016;9(1):1–10.
5. Spetz J, Moslehi J, Sarosiek K. Radiation-induced cardiovascular toxicity : mechanism, prevention, and treatment. *Curr. Treat. Options Cardiovasc. Med*. 2018; 20, 1-1.
6. Van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. *FEBS J*. 2021 Nov;288(21):6095–111.
7. Singh J, Iqbal S, Gajula S, et al. (May 01, 2024) Assessment of Chemotherapy-Induced Cardiac Dysfunction in Breast Cancer Patients: A Prospective Study. *Cureus* 16(5): e59461. doi:10.7759/cureus.59461;4-8
8. Wahdiyat M. Gambaran Perubahan Ekokardiografi pada Pasien Kanker yang Mendapat Terapi Doxorubicin [thesis]. Makassar: Fakultas Kedokteran Universitas Hasanuddin; 2022.
9. Alexander RL, Teresa L, Liam SC, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *European Heart Journal*. 2023;43(41):4229-361.
10. Tonry C, Russell-Hallinan A, McCune C, et al. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. *Cardiovasc Res*. 2023;119(3):710–28.
11. Manrique CR, Park M, Tiwari N, et al. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. *Clin Med Insights Cardiol*. 2017;11: 2.

12. Lopez-Fernandez T, Farmakis D, Ameri P, *et al.* European Society of Cardiology Core Curriculum for cardio-oncology. *Eur J Heart Fail* 2024; 26:754–71.
13. Shi T, Jiang C, Zhu C, *et al.* Insurance disparity in cardiovascular mortality among non-elderly cancer survivors. *Cardiooncology*. 2021;7:11.
14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72:7–33.
15. Addison D, Branch M, Baik AH, *et al.* Equity in cardio-oncology care and research: a scientific statement from the American Heart Association. *Circulation* 2023;148:297–308.
16. Barbieri A, Camilli M, Bisceglia I, *et al.* Current use of echocardiography in cardio-oncology: nationwide real-world data from an ANMCO/SIECVI joint survey. *Eur Heart J Imaging Methods Pract*. 2024 Aug 12;2(3).
17. Herrmann J, Lenihan D, Armenian S, *et al.* Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J*. 2022;43(4):280–99.
18. Perez IE, Taveras Alam S, Hernandez GA, *et al.* Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. *Clin Med Insights Cardiol*. 2019;13: 1-9
19. Yu AF, Moore ZR, Moskowitz CS, *et al.* Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. *JAMA Cardiol*. 2023 Jul;8(7):697–702.
20. Kent EE, Forsythe LP, Yabroff KR, *et al.* Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? *Cancer*. 2013;119:3710–3717.
21. Zafar SY, McNeil RB, Thomas CM, *et al.* Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. *J Oncol Pract*. 2015;11:145–150.
22. Ahmad J, Muthyala A, Kumar A, *et al.* Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement. *Curr Cardiol Rep*. 2022 Sep;24(9):1117-1127.
23. Caplin DA, Smith KR, Ness KK, Hanson HA, Smith SM, Nathan PC, *et al.* Effect of Population Socioeconomic and Health System Factors on Medical Care of Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. *J Adolesc Young Adult Oncol*. 2017;6:74–82.
24. Tromp J, Ouwerkerk W, Teng T-HK, Cleland JGF, Bamadhaj S, Angermann CE, *et al.* Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. *Eur Heart J*. 2022;ehac103.

25. Ng CT, Tan LL, Sohn IS, et al. Advancing Cardio-Oncology in Asia. *Korean Circ J*. 2023 Feb;53(2):69-91.
26. Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors. *Epidemiology (Cambridge, Mass)* 2016, 27(1):6.
27. Stankovic I, Dweck MR, Marsan NA, et al. The EACVI survey on cardiac imaging in cardio-oncology. *Eur Heart J Cardiovasc Imaging* 2021;22: 367–7.
28. Okwuosa, T, Prabhu, N, Patel, H. et al. The Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (or Onco-Cardiology) and Call to Action. *JACC*. 2018 Jul, 72 (2) 228–232.
29. McDonald JP, MacNamara JP, Zaha VG. Challenges in Implementing Optimal Echocardiographic Screening in Cardio-Oncology. *Curr Treat Options Cardiovasc Med*. 2019 Jul 10;21(8):39.
30. Barbieri A, Ciampi Q, Barchitta A, et al. Current national availability of advanced echocardiography imaging: real world data from an Italian Society of Echocardiography and Cardiovascular Imaging survey. *Eur Heart J Imaging Methods Practice* 2023;1.
31. Chavez-Macgregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, et al. Cardiac monitoring during adjuvant Trastuzumab-based chemotherapy among older patients with breast Cancer. *J Clin Oncol*. 2015;33(19):2176–83.
32. Okwuosa TM, Barac A. Burgeoning Cardio-Oncology Programs: Challenges and Opportunities for Early Career Cardiologists/Faculty Directors. *J Am Coll Cardiol*. 2015 Sep 8;66(10):1193-7.
33. Roflin E, Liberty IA, Pariyana. Populasi, sampel, variabel dalam penelitian kedokteran. *Naya Expanding Management*. 2021. (1): 23–24.
34. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2023. Jakarta: Kementerian Kesehatan RI; 2024.
35. Kementerian Kesehatan Republik Indonesia. Hasil utama Riskesdas. Jakarta; 2018.
36. Canale ML, Turazza F, Lestuzzi C, et al. Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey. *Front Cardiovasc Med*. 2021 Jun 16;8:677544.
37. Bloom MW, Vo JB, Rodgers JE, C, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. *J Card Fail*. 2025 Feb;31(2):415-55.
38. Addison D, Neilan TG, Barac A, et.al. Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. *Circulation*. 2023;148:1271–1286.
39. Andres MS, Murphy T, Poku N, Nazir MS, et.al. The United Kingdom's First Cardio-Oncology Service: A Decade of Growth and Evolution. *JACC CardioOncol*. 2024 Feb 6;6(2):310-312.

40. Narezkina A, Narayan HK, Zemljic-Harpf AE. Molecular mechanisms of anthracycline cardiovascular toxicity. Clin Sci (Lond). 2021 May 28;135(10):1311-1332.
41. Greenlee H, Iribarren C, Rana JS, et al. Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022 May 20;40(15):1647-1658.
42. Khoury K, Lynce F, Barac A, et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat. 2021 Feb;185(3):863-868.
43. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171–190.
44. Park H, Lee N, Hwang CH, et al. Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics-Related Cardiac Dysfunction. JACC CardioOncol. 2024 Sep 17;6(5):699-71

